Sustained-release agent of nitric acid dinitrate and preparation method thereof

Abstract

An isosorbide dinitrate sustained-release preparation is a tablet which consists of isosorbide dinitrate, sustained-release materials and other pharmaceutical excipients, wherein, the sustained-release materials are selected from hypromellose (E4M) and carmellose sodium. As the drug is released in digestive tract according to the procedure after the oral administration, the effective plasma drug concentration in human body can be maintained stably and sustainedly, therefore the invention has the advantages of good healing efficacy, long drug effect, less side effects, small number of the times of the administration of the patients, convenient usage and so on; the invention not only has the function of treating and alleviating angina symptoms, but also has the special advantages of preventing sudden onset and protecting the daily lives of the patients and safely passing through the incidence peak of the diseases, therefore, the invention provides reliable means and great convenience for the treatment of the patients and the self-prevention of sudden onset; the price of the drug is cheap, which is conductive to the administration of ordinary patients.

Description

Isosorbide dinitrate sustained-release agent and preparation method thereof technical field The invention relates to a medicine slow-release preparation, specifically an isosorbide dinitrate slow-release preparation for treating angina pectoris, and a preparation method of the slow-release preparation. technical background Angina pectoris is a common clinical syndrome in cardiovascular emergencies. Most patients have coronary heart disease or myocardial disease. Threat or unexpected sudden death. The traditional treatment method is to use isosorbide dinitrate tablets to treat angina pectoris, and the dosage form is generally a common tablet. Patients with angina pectoris often develop symptoms at 1 to 3 o'clock at night (morning peak period) and after the patient wakes up (morning peak period). Due to the short half-life of ordinary tablet drugs, generally 1.8 to 2 hours, the drug effect lasts for a short time and requires several times a day. Repeated administration has...

AI Technical Summary

Problems solved by technology

Patients with angina pectoris often develop symptoms at 1 to 3 o'clock at night (morning peak period) and after the patient wakes up (morning peak period). Due to the short half-life of ordinary tablet drugs, generally 1.8 to 2 hours, the drug effect lasts for a short time and requires several times a day. Repeated administration, side effects are relatively large and it is difficult to prevent sudden onset, so it increases the difficulty and inconvenience for patients to rest, work, travel and go out

Isosorbide Mononitrate Sustained-release Tablets, although similar to this product, are expensive and not suitable for a large number of ordinary patients